Markets:

Overview

News

Currencies

International

Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

4.005 -0.025 (-0.62%)

Delayed Quote Updated: 1:33 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >

ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Neffy market share doubled as prescriber count tripled year over year.

Via The Motley Fool

Topics Earnings

ARS Pharmaceuticals Q2 Earnings Call Highlights ↗

August 13, 2026

ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused...

Via MarketBeat

Topics Earnings

ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 13, 2026

ARS Pharmaceuticals (NASDAQ:SPRY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide...

Via Benzinga

Topics Earnings

Which stocks are moving before the opening bell on Thursday? ↗

June 25, 2026

Via Chartmill

ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗

May 15, 2026

Via Chartmill

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Outlook For ARS Pharmaceuticals ↗

November 07, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

June 24, 2026

Via Chartmill

ARS Pharma (SPRY) Q1 2026 Earnings Transcript ↗

May 18, 2026

ARS Pharma (SPRY) Q1 2026 Earnings Transcript

Via The Motley Fool

ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗

May 15, 2026

ARS Pharma (SPRY) Q4 2025 Earnings Transcript

Via The Motley Fool

Earnings Outlook For ARS Pharmaceuticals ↗

August 12, 2025

Via Benzinga

ARS Pharmaceuticals's Earnings: A Preview ↗

May 13, 2025

Via Benzinga

ARS Pharmaceuticals Q1 Earnings Call Highlights ↗

May 15, 2026

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for...

Via MarketBeat

Topics Earnings

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

May 15, 2026

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.

Via Benzinga

Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗

February 16, 2026

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Via The Motley Fool

ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗

November 10, 2025

ARS Pharma SPRY Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗

November 10, 2025

ARS Pharma beats Q3 2025 revenue estimates with strong neffy sales. The company reports a wider loss but shows robust commercial growth and global expansion.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 03, 2025

Via Benzinga

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗

September 23, 2025

ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns.

Via Benzinga

ARS Pharma Sales Jump 3,040% in Q2 ↗

August 13, 2025

Via The Motley Fool

ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists ↗

August 13, 2025

ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway.

Via Chartmill

Earnings Scheduled For August 13, 2025 ↗

August 13, 2025

Via Benzinga

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs ↗

June 12, 2025

Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 20, 2025

Via Benzinga

Which stocks are gapping on Thursday? ↗

March 20, 2025

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. ↗

March 20, 2025

The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions.

Via Investor's Business Daily

Earnings Scheduled For May 14, 2025 ↗

May 14, 2025

Via Benzinga

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday ↗

March 20, 2025

Via Benzinga

Earnings Scheduled For March 20, 2025 ↗

March 20, 2025

Via Benzinga

FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment ↗

March 06, 2025

FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.